

## Product Information

### apo-Transferrin human

Product Number **T 4382**

#### Product Description

Molecular Weight: approximately 76-81 kDa

CAS Number: 11096-37-0

$\lambda_{\max}$ : 280 nm (water)<sup>1</sup>

This product is supplied as a lyophilized powder of human apo-transferrin.

Transferrin is a glycoprotein with homologous N-terminal and C-terminal iron-binding domains.<sup>2</sup> Transferrin is related to several other iron-binding proteins including lactoferrin, melanotransferrin, and ovotransferrin. These molecules comprise the transferrin superfamily. All members of this superfamily have similar polypeptide folding patterns. The N-terminal and C-terminal domains of these proteins are globular moieties of about 330 amino acids. Each of these domains is divided into two sub-domains, with the iron- and anion-binding sites found within the intersubdomain cleft. The binding cleft opens with iron release, and closes with iron binding. Transferrin binds iron with an association constant of approximately  $10^{22} \text{ M}^{-1}$ .<sup>3</sup> Ferric iron couples to transferrin only in the presence of an anion (usually carbonate) that serves as a bridging ligand between metal and protein, excluding water from the two coordination sites.<sup>3-5</sup> Without the anion cofactor, iron binding to transferrin is negligible. In the presence of anions, ferric transferrin is resistant to all but the most potent chelators. The remaining four coordination sites are provided by the transferrin protein - a histidine nitrogen, an aspartic acid carboxylate oxygen, and two tyrosine phenolate oxygens.<sup>6,7</sup> Available evidence suggests that anion-binding takes place prior to iron-binding. Iron release from transferrin involves protonation of the carbonate anion, loosening the metal-protein bond.

The sum of all iron binding sites on transferrin constitutes the total iron binding capacity (TIBC) of plasma. Under normal circumstances, approximately one-third of transferrin iron-binding pockets are filled.

Consequently, with the exception of iron overload where all the transferrin binding sites are occupied, non-transferrin-bound iron in the circulation is virtually nonexistent. The normal half-life of iron in the circulation is about 75 minutes.<sup>8</sup> The absolute amount of iron released from transferrin per unit time is the plasma iron turnover (PIT). Radioactive tracer studies indicate that at least 80% of the iron bound to circulating transferrin is delivered to the bone marrow and incorporated into newly formed erythrocytes.<sup>9,10</sup> Other major sites of iron delivery include the liver, which is a primary depot for stored iron, and the spleen. Hepatic iron is found in both reticuloendothelial cells and hepatocytes.<sup>11</sup>

Iron is taken into cells by receptor-mediated endocytosis of monoferric and diferric transferrin.<sup>12-14</sup> Receptors on the outer face of the plasma membrane bind iron-loaded transferrin with a very high affinity. The C-terminal domain of transferrin appears to mediate receptor binding.<sup>15</sup> Diferric transferrin binds with higher affinity than monoferric transferrin or apotransferrin.<sup>16,17</sup> The dissociation constant ( $K_d$ ) for bound diferric transferrin ranges from  $10^{-7} \text{ M}$  to  $10^{-9} \text{ M}$  at physiologic pH, depending on the species and tissue assayed.<sup>18,19</sup> The  $K_d$  of monoferric transferrin is approximately  $10^{-6} \text{ M}$ . The concentration of circulating transferrin is about 25 mM. Therefore, cellular transferrin receptors ordinarily are fully saturated.

After binding to its receptor on the cell surface, transferrin is rapidly internalized by invagination of clathrin-coated pits with formation of endocytic vesicles.<sup>20,21</sup> Following internalization into endosomes, the transferrin-receptor complex is subjected to a drop in endosomal pH (pH lowered to 5.5),<sup>22,23</sup> which weakens the association between iron and the transferrin. With the assistance of an oxidoreductase, the bound iron is then reduced from the  $\text{Fe}^{3+}$  state to  $\text{Fe}^{2+}$ , leading to the release of the iron from the transferrin.<sup>24,25</sup> Conformational changes in the transferrin receptor also play a role in this iron release.<sup>26,27</sup>

Following the release of iron, receptor-bound apo-transferrin recycles to the cell surface rather than being transported to lysosomes for degradation. The neutral pH at the cell surface promotes the release of the apo-transferrin from its receptor,<sup>15</sup> where it can again circulate and bind additional iron to undergo further rounds of iron delivery to cells.<sup>13,22,23</sup> The average transferrin molecule, with a half-life of eight days, may be used up to one hundred times for iron delivery.<sup>28</sup>

To form holo-transferrin (i.e., to saturate apo-transferrin with iron), the following procedure can be followed. The apo-transferrin is mixed with 2% of its mass in ferrous ammonium sulfate hexahydrate (Product No. F 3754) with sodium carbonate buffer, pH 5.9, for 1.5 hours. The pH is then raised to 8.5 with sodium carbonate and the solution is mixed for an additional 1.5 - 2 hours. The sample is then dialyzed against water to remove the buffer salts.

#### Precautions and Disclaimer

For Laboratory Use Only. Not for drug, household or other uses.

#### Preparation Instructions

This product is soluble in water (2 mg/ml).

#### Storage/Stability

Aqueous solutions of apo-transferrin should be stable at 4 °C for 5-10 days. Solutions should be filter-sterilized for maximum stability.

#### References

1. Koechlin, B. A. Preparation and Properties of Serum and Plasma Proteins. XXVIII. The  $\beta$ 1-Metal-combining Protein of Human Plasma. *J. Am. Chem. Soc.* **74**, 2649-2652 (1952).
2. Huebers, H. A., and Finch, C. A. The physiology of transferrin and transferrin receptors. *Physiological Reviews* **67**, 520-582 (1987).
3. Aisen, P., and Listowsky, I., Iron transport and storage proteins. *Annu Rev Biochem.*, **49**, 357-393 (1980).
4. Harris, D. C., and Aisen, P., in *Iron Carriers and Iron Proteins*, Loehr, T. M., et al., eds., VCH Publishers (Weinheim: 1989), pp. 239-351.
5. Shongwe, M. S., et al., Anion binding by human lactoferrin: results from crystallographic and physicochemical studies. *Biochemistry*, **31(18)**, 4451-4458 (1992).
6. Bailey, S. et al., Molecular structure of serum transferrin at 3.3 Å resolution. *Biochemistry*, **27(15)**, 5804-5812 (1988).
7. Anderson, B. F., et al., Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 Å resolution., *J. Mol. Biol.*, **209(4)**, 711-734 (1989).
8. Huff, R. L., et al., Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. *J. Clin. Invest.*, **29**, 1041 (1950).
9. Jandl, J. H., and Katz, J. H., The plasma-to-cell cycle of transferrin. *J. Clin. Invest.*, **42**, 314-326 (1963).
10. Finch, C., et al., Effect of transfused reticulocytes on iron exchange. *Blood*, **59(2)**, 364-369 (1982).
11. Inman, R. S., and Wessling-Resnick, M., Characterization of transferrin-independent iron transport in K562 cells. Unique properties provide evidence for multiple pathways of iron uptake. *J. Biol. Chem.*, **268(12)**, 8521-8528 (1993).
12. Karin, M., and Mintz, B., Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. *J. Biol. Chem.*, **256(7)**, 3245-3252 (1981).
13. Klausner, R. D., et al., Receptor-mediated endocytosis of transferrin in K562 cells. *J. Biol. Chem.*, **258(8)**, 4715-4724 (1983).
14. Iacopetta, B. J., and Morgan, E. H., The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. *J. Biol. Chem.*, **258(15)**, 9108-9115 (1983).
15. Zak, O., et al., Primary receptor-recognition site of human transferrin is in the C-terminal lobe. *J. Biol. Chem.*, **269(10)**, 7110-7114 (1994).
16. Huebers, H. A., et al., Heterogeneity of the plasma iron pool: explanation of the Fletcher-Huehns phenomenon. *Am. J. Physiol.*, **247(2 Pt 2)**, R280-283 (1984).
17. Young, S. P., et al., The effect of the iron saturation of transferrin on its binding and uptake by rabbit reticulocytes. *Biochem. J.*, **219(2)**, 505-510 (1984).
18. Stein, B. S., and Sussman, H. H., Peptide mapping of the human transferrin receptor in normal and transformed cells. *J. Biol. Chem.*, **258(4)**, 2668-2673 (1983).
19. Sawyer, S. T., and Krantz, S. B., Transferrin receptor number, synthesis and endocytosis during erythropoietin-induced maturation of Friend virus-infected erythroid cells. *J. Biol. Chem.*, **261(20)**, 9187-9195 (1986).
20. Rothenberger, S., et al., Endocytosis of the transferrin receptor requires the cytoplasmic domain but not its phosphorylation site. *Cell*, **49(3)**, 423-431 (1987).

21. McGraw, T. E., and Maxfield, F. R., Human transferrin receptor internalization is partly dependent upon an aromatic amino acid in the cytoplasmic domain. *Cell Regul.*, **1(4)**, 369-377 (1990).
22. van Renswoude, J., et al., Receptor-mediated endocytosis and the uptake of iron in K562 cells: Identification of a non-lysosomal acidic compartment. *Proc. Natl. Acad. Sci. USA.*, **79(20)**, 6186-6190 (1982).
23. Dautry-Varsat, A., et al., pH and the recycling of transferrin during receptor-mediated endocytosis. *Proc. Natl. Acad. Sci. USA*, **80(8)**, 2258-2262 (1983).
24. Low, H., et al., Involvement of transferrin in the reduction of iron by the transplasma membrane electron transport system. *J. Bioenerg. Biomembr.*, **19(5)**, 535-549 (1987).
25. Thorstensen, K., and Romslo, I., Uptake of iron from transferrin by isolated rat hepatocytes. A redox-mediated plasma membrane process? *J. Biol. Chem.*, **263(18)**, 8844-8850 (1988).
26. Bali, P. K., et al., A new role for the transferrin receptor in the release of iron from transferrin. *Biochemistry*, **30(2)**, 324-328 (1991).
27. Sipe, D. M., and Murphy, R. F., Binding to cellular receptors results in increased iron release from transferrin at mildly acidic pH. *J. Biol. Chem.*, **266(13)**, 8002-8007 (1991)
28. Harford, J. B., et al., In *The Molecular Basis of Blood Diseases*, Stamatoyannopoulos, G., et al., eds., W. B. Saunders Co. (Philadelphia, PA: 1994), pp. 351-378.

CMH/RXR 12/03

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.